Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]